SCHEMBL325532

SCHEMBL325532

Oc1ccc(Oc2ccccc2Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.56
NR1H2 P55055 1/20 0.56
BAX Q07812 1/20 0.56
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
ESR1 P03372 1/20 0.52
ESR2 Q92731 1/20 0.52
TTR P02766 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 4/20 0.42
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30812150 1.00 LTA4H (0.56) LTA4HNR1H2BAXMEN1KMT2A
SCHEMBL74839 0.89 ALDH1A1 (0.52) LTA4HKMT2AALDH1A1MAPK1HTT
SCHEMBL3843172 0.87 ALDH1A1 (0.50) LTA4HNR1H2BAXKMT2AALDH1A1
SCHEMBL4211500 0.84 LTA4H (0.68) LTA4HNR1H2BAXMEN1KMT2A
SCHEMBL10766889 0.84 MEN1 (0.48) LTA4HNR1H2BAXMEN1KMT2A
SCHEMBL8954758 0.83 LTA4H (0.55) LTA4HNR1H2BAXKMT2AALDH1A1
SCHEMBL3845666 0.83 SLC6A4 (0.53) MEN1KMT2AALDH1A1MAPK1HTT
SCHEMBL9483870 0.82 LTA4H (0.73) LTA4HNR1H2BAXMEN1KMT2A
SCHEMBL130304 0.82 LTA4H (0.52) LTA4HNR1H2BAXKMT2AALDH1A1
SCHEMBL3898531 0.81 ALDH1A1 (0.49) MEN1KMT2AALDH1A1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388605-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2025-12-25 US disclosed
WO-2024054956-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 WO disclosed
WO-2024054955-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 WO disclosed
WO-2024054955-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 WO disclosed
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388605-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE BRD4, BRDT, BICRA LTA4H 3707/4885NR1H2 85/4885BAX 2313/4885
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases MMP9, MMP1, MMP2 LTA4H 504/4885NR1H2 2158/4885BAX 4059/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 LTA4H 229/4885NR1H2 2072/4885BAX 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.